Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies

A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% (Encube Ethicals) Compared to Elimite™ Cream (Permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies

Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5%in the Treatment of Scabies.

Study Overview

• Status: Completed
• Conditions: Scabies
• Intervention / Treatment: Drug: Elimite™ Cream (permethrin) 5%; Drug: Permethrin Cream, 5%

Detailed Description

A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5% (Encube Ethicals) Compared to Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies.

The objectives of this study are to:

1. Evaluate the therapeutic equivalence of the Test formulation, Permethrin Cream, 5% (Encube Ethicals) to the marketed product, Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.) in patients with scabies.
2. Compare the safety of Test and Reference treatments in patients with scabies.

• Study Type: Interventional
• Enrollment (Actual): 254
• Phase: Phase 3

Contacts and Locations

Study Locations

• El Salvador
  • San Salvador, El Salvador, O1101
    • Clinica Dermatologica/APF Research International
  • San Salvador, El Salvador, O1501
    • Clinica Dermatologica Y Cirugia de Piel/APF Research International
  • San Salvador, El Salvador
    • Clinica de la Doctora Laura Vargas
• Puerto Rico
  • Aguas Buenas, Puerto Rico, OO703
    • APF Research International
  • Loiza, Puerto Rico, OO772
    • APF Research International
• United States
  • Arkansas
    • Little Rock, Arkansas, United States, 72212
      • Applied Research Center of Arkansas
  • California
    • Anaheim, California, United States, 92804
      • St. Josephs Clinical Research
    • Long Beach, California, United States, 90806
      • Long Beach Clinical Trials
    • Pasadena, California, United States, 91105
      • Havana Research Institute
  • Florida
    • Hialeah, Florida, United States, 33015
      • Integrity Clinical Research Center, Inc.
    • Kissimmee, Florida, United States, 34744
      • The Chappel Group Research
    • Sweetwater, Florida, United States, 33172
      • Lenus Research & Medical Group, LLC
  • Pennsylvania
    • Hazleton, Pennsylvania, United States, 18201
      • DermDox Cetners for Dermatology
  • Texas
    • Houston, Texas, United States, 77055
      • West Houston Clinical Research Services
    • San Antonio, Texas, United States, 78215
      • Sun Research Instiute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 2 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Male or non-pregnant, non-lactating female, 2 years of age or older.
2. If female and of childbearing potential, prepared to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., double barrier methods, intrauterine device (IUD), oral, transdermal or injected hormonal contraceptives). Female patients using hormonal contraceptives should have been on the same product/dosing regimen for at least 28 days before baseline and should not change this regimen during the study.
3. Signed informed consent that meets all criteria of current FDA and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) regulations. For patients who are considered minors in the state the study is being conducted (< 18 years in most states) the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form, as appropriate. Patients 11-17 years of age will read and sign an Independent Review Board (IRB)-approved assent form and patients 6-10 years of age will provide verbal assent. Patients 2-5 years of age will be exempt from providing assent based on the child's comprehension and cognitive skills.
4. Clinical diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions at the classic sites of infestation.
5. Parasitological confirmation of clinical diagnosis with demonstration under light microscope of mites and/or their products (larvae, eggs or fecal material).
6. Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching/pruritus.
7. Ability to apply or have study product applied as directed. If patient is a child, then parent/guardian will apply study product to him/her.

Exclusion Criteria:

1. Patients who are pregnant, lactating, or planning to become pregnant during the study.
2. Any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events (AEs).
3. Known hypersensitivity to permethrin cream or any of its components.
4. Use of any systemic or topical acaricide or ectoparasiticide within one month before Screening.
5. Patient has signs of a systemic infection or is receiving systemic therapy for an infectious disease.
6. Patients with severe cutaneous bacterial or fungal infections requiring therapy (including systemic and topical antibiotics) or coexisting dermatological disorder that could interfere with the diagnosis and subsequent monitoring of scabies) or heavily crusted with lesions consistent with Norwegian scabies.
7. Patients with an underlying immunodeficient state (including prolonged treatment with corticosteroids), immunosuppressive disorders requiring therapy, severe systemic disease and history of HIV infection.
8. Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.
9. Family members of employees of the clinic or Investigator.
10. Patients who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.
11. Patients whose close personal contacts will not or are not willing to comply with standard of care for Scabies management.
12. Receipt of any drug as part of a research study within 30 days before Screening.
13. History of seizures.
14. Use of systemic corticosteroids within two weeks before Screening.
15. Use of topical corticosteroids within one week before Screening.
16. Previous participation in this study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Reference: Elimite™ Cream; Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)	Drug: Elimite™ Cream (permethrin) 5%; Permethrin Cream 5%; Other Names: Elimite™ Cream
Experimental: Test: Permethrin Cream, 5%; Test: Permethrin Cream, 5% (Encube Ethicals)	Drug: Permethrin Cream, 5%; Permethrin Cream 5%

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present). Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Day 28 ± 4

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Patients With a Therapeutic Cure That Completed Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 4 Days.	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present). Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 4 Days
Number of Patients With a Therapeutic Cure That Completed Visit 2 Within 14 ± 2 Days and Visit 3 Between Day 26 and Day 32, Inclusive.	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present). Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Visit 2 within 14 ± 2 days and Visit 3 between Day 26 and Day 32, inclusive.
Number of Patients With a Therapeutic Cure That Completed Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 2 Days.	Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present). Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).	Visit 2 Within 14 ± 2 Days and Visit 3 Within 28 ± 2 Days

Collaborators and Investigators

• Sponsor: Encube Ethicals Pvt. Ltd.
• Collaborators: Novum Pharmaceutical Research Services
• Investigators: Study Director: Pratik Kamani, Encube Ethicals Pvt. Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2017
• Primary Completion (Actual): November 11, 2017
• Study Completion (Actual): November 11, 2017

Study Registration Dates

• First Submitted: May 31, 2017
• First Submitted That Met QC Criteria: June 5, 2017
• First Posted (Actual): June 7, 2017

Study Record Updates

• Last Update Posted (Actual): March 26, 2019
• Last Update Submitted That Met QC Criteria: March 14, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Infections; Parasitic Diseases; Ectoparasitic Infestations; Skin Diseases, Parasitic; Skin Diseases, Infectious; Mite Infestations; Scabies; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Permethrin
• Other Study ID Numbers: 71675502

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No